Clinical trials: Circulating Tumor Cell;
Non-squamous Non-small Cell Lung Cancer
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with…
- Trial name
- CARMEN-LC06 (NCT05245071)
- Testing
- Tusamitamab ravtansine
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Sanofi
Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE
- Conditions
- Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
- Trial name
- Mona-Lisa (NCT05390112)
- Testing
- DNA
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Rouen
Resectable Non-small Lung Cancer
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer
With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer.
- Trial name
- LYMPHOLUNG (NCT02551211)
- Testing
- blood drawn, surgical resection of cancer
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Prostate Cancer, Circulating Tumor Cell
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients.
- Conditions
- Prostate Cancer, Circulating Tumor Cell, Leukapheresis
- Trial name
- NCT06469710
- Testing
- leukapheresis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Bone Metastases of a Malignant Tumor
Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells
The purpose of this study is to investigate the effects of aminobiphosphonate treatment on the phenotype and function of circulating Vgamma9Vdelta2-T cells and to determine whether these effects are inhibited by simultaneous…
- Trial name
- NCT01179464
- Testing
- Aminobiphosphonate, Simvastatin
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- Amsterdam UMC, location VUmc
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lymphoma, Large B-Cell, Diffuse
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA
The aim of the project is to clarify whether DLBCL exhibits mutational diversity among different lymph node tumors in one and the same patient.
- Trial name
- NCT04763148
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Herlev Hospital
Prostate Cancer
CTC Immune Checkpoint
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and…
- Trial name
- NCT02456571
- Testing
- CTC biomarker expression prevalence
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Renal Cell Carcinoma
Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer
This study investigates the role of circulating and urinary exosomal microRNAs (miRNAs) as potential biomarkers for predicting response to systemic therapy in patients with advanced renal cell carcinoma.
- Trial name
- EXO-RENAL2 (NCT07436416)
- Testing
- Circulating and Urinary Exosomal miRNA Analysis
- Where
- Slovenia
- Volunteers
- 91 people
- Sponsor
- Institute of Oncology Ljubljana
Carcinoma, Non-small-cell Lung Cancer
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and…
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02907606
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer Metastatic
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring.
- Trial name
- PRELUCA (NCT05889247)
- Testing
- Circulating tumor DNA treatment monitoring
- Where
- 5 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- Zealand University Hospital
Breast Cancer
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00382018
- Testing
- chemotherapy
- Where
- 296 sites in United States
- Volunteers
- 624 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2.
- Trial name
- NCT02029209
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)
The purpose of the study is to determine whether the type of anesthesia during breast cancer surgery has any impact on the way a patient's immune system functions for a brief period after surgery.
- Trial name
- CTC (NCT01716065)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Defense and Veterans Center for Integrative Pain Management
Breast Cancer, Metastatic, Breast Cancer Invasive
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
- Conditions
- Breast Cancer, Metastatic, Breast Cancer Invasive, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- PROBE-CTC (NCT06807502)
- Testing
- The DM/DIV ScreenCell is the experimental product studied during this research
- Where
- France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- ScreenCell
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Prospective ctDNA Testing in Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment.
- Trial name
- NCT07878351
- Testing
- Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such as R-CHOP, Pola-R-CHP, or DA-EPOCH-R.
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Glioma, miRNA
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
With around 3,400 cases per year in France, diffuse gliomas are the most common primary tumours of the central nervous system. Their grade varies from 2 to 4.
- Conditions
- Glioma, miRNA, Low-grade Glioma, Biomarkers
- Trial name
- GLIBAMIR (NCT06610851)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Caen
Melanoma
CAcTUS - Circulating Tumour DNA Guided Switch
The stay aims to determine whether switching from targeted therapy to immunotherapy based on a decrease in levels of circulating tumour DNA in the blood, will improve the outcome in melanoma patients.
- Trial name
- CAcTUS (NCT03808441)
- Testing
- ctDNA analysis
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Christie NHS Foundation Trust
Head and Neck Cancer, Advanced Cancer
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC
- Trial name
- NCT04606940
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto